Capricor Investors Have Until September 28 to Join Lawsuit
News related to:Capricor Therapeutics, Inc · 1 min read
NEW YORK, Sept. 13, 2026 /CourierPR/ -- Rosen Law Firm, a global investor rights law firm, has reminded investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of an important deadline. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, inclusive, are eligible to join a securities fraud lawsuit.
According to the lawsuit, Capricor Therapeutics, Inc., made materially false and misleading statements, or failed to disclose key information regarding its clinical data and regulatory approval process for Deramiocel, a cell therapy. The lawsuit alleges that Capricor adopted changes to the pre-specified statistical analysis plan without the FDA's agreement, which could significantly impact the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy.
The lawsuit claims that these actions misled investors and resulted in a substantial risk to the company's regulatory approval. As a result, the company's positive statements about its business, operations, and prospects were deemed materially misleading and lacked a reasonable basis.
Rosen Law Firm is urging investors to act quickly. The firm reminds investors that they have until September 28, 2026, to move the court to become a lead plaintiff. Lead plaintiffs are representative parties acting on behalf of other class members in directing the litigation.
The Rosen Law Firm has a history of success in leadership roles, having achieved the largest ever securities class action settlement against a Chinese company. The firm has been ranked in the top 4 for securities class actions in 2017 and has recovered billions of dollars for investors. In 2019, the firm secured over $438 million for investors, and in 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar.
The lawsuit alleges that Capricor's actions violated federal securities laws, and investors who purchased Capricor securities during the class period may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement.